reduce mortality in mechanically ventilated patients by a third. Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.Remdesivir can decrease the length of time a person has COVID-19 and does provide some benefit to some people, but it has little effect on its own.
Remdesivir also requires intravenous administration, which lessens its clinical use.Researchers with the NIH have found that the oral antiviral drug MK-4482 effectively fights SARS-CoV-2 infections in hamsters.MK-4482, which scientists are now testing in human clinical trials, reduced the level of SARS-CoV-2 replication and disease damage in the lungs of hamsters.